Search Results

• • 14 

    Academic Journals

  • Sort by: sorttype.publication.date.desc Newest sorttype.publication.date.asc Oldest sorttype.relevance Relevance

• The urgent need for metallo-[beta]-lactamase inhibitors: an unattended global threat.

  Authors:Maria F Mojica, Maria-Agustina Rossi, Alejandro J Vila, and Robert A BonomoFrom:The Lancet Infectious Diseases (Vol. 22, Issue 1) Peer-Reviewed

  Jan. 2022327 words Brief article

   Abstract Only

• 100 years of Mycobacterium bovis bacille Calmette-Guerin.

  Authors:Christoph Lange, Peter Aaby, Marcel A Behr, Peter R Donald, Stefan H E Kaufmann, Mihai G Netea, et al.From:The Lancet Infectious Diseases (Vol. 22, Issue 1) Peer-Reviewed

  Jan. 2022420 words Article

   Abstract Only

• Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial.

  Authors:David Ishola, Daniela Manno, Muhammed O Afolabi, Babajide Keshinro, Viki Bockstal, Baimba Rogers, et al.From:The Lancet Infectious Diseases (Vol. 22, Issue 1) Peer-Reviewed

  Jan. 20221,830 words Article

   Abstract Only

• Comparison of three tests for latent tuberculosis infection in high-risk people in the USA: an observational cohort study.

  Authors:Christine S Ho, Pei-Jean I Feng, Masahiro Narita, Jason E Stout, Michael Chen, Lisa Pascopella, et al.From:The Lancet Infectious Diseases (Vol. 22, Issue 1) Peer-Reviewed

  Jan. 2022771 words Article

   Abstract Only

• Comparison of the safety and immunogenicity of a novel Matrix-M-adjuvanted nanoparticle influenza vaccine with a quadrivalent seasonal influenza vaccine in older adults: a phase 3 randomised controlled trial.

  Authors:Vivek Shinde, Iksung Cho, Joyce S Plested, Sapeckshita Agrawal, Jamie Fiske, Rongman Cai, et al.From:The Lancet Infectious Diseases (Vol. 22, Issue 1) Peer-Reviewed

  Jan. 2022593 words Article

   Abstract Only

• The importance of enterovirus surveillance in a post-polio world.

  Authors:Thea K Fischer, Peter Simmonds, and Heli HarvalaFrom:The Lancet Infectious Diseases (Vol. 22, Issue 1) Peer-Reviewed

  Jan. 2022302 words Brief article

   Abstract Only

• Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.

  Authors:Denis Sauré, Miguel O'Ryan, Juan Pablo Torres, Marcela Zuniga, Emilio Santelices, and Leonardo J BassoFrom:The Lancet Infectious Diseases (Vol. 22, Issue 1) Peer-Reviewed

  Jan. 2022675 words Report

   Abstract Only

• Bell's palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study.

  Authors:Eric Yuk Fai Wan, Celine Sze Ling Chui, Francisco Tsz Tsun Lai, Esther Wai Yin Chan, Xue Li, Vincent Ka Chun Yan, et al.From:The Lancet Infectious Diseases (Vol. 22, Issue 1) Peer-Reviewed

  Jan. 2022909 words Report

   Abstract Only

• Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study.

  Authors:Michela Antonelli, Rose S Penfold, Jordi Merino, Carole H Sudre, Erika Molteni, Sarah Berry, et al.From:The Lancet Infectious Diseases (Vol. 22, Issue 1) Peer-Reviewed

  Jan. 20221,049 words Clinical report

   Abstract Only

• Effect of preventive chemotherapy with praziquantel on schistosomiasis among school-aged children in sub-Saharan Africa: a spatiotemporal modelling study.

  Authors:Christos Kokaliaris, Amadou Garba, Martin Matuska, Rachel N Bronzan, Daniel G Colley, Ameyo M Dorkenoo, et al.From:The Lancet Infectious Diseases (Vol. 22, Issue 1) Peer-Reviewed

  Jan. 2022709 words Article

   Abstract Only

• Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study.

  Authors:Katherine A Twohig, Tommy Nyberg, Asad Zaidi, Simon Thelwall, Mary A Sinnathamby, Shirin Aliabadi, et al.From:The Lancet Infectious Diseases (Vol. 22, Issue 1) Peer-Reviewed

  Jan. 20221,798 words Article

   Abstract Only

• Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial.

  Authors:Muhammed O Afolabi, David Ishola, Daniela Manno, Babajide Keshinro, Viki Bockstal, Baimba Rogers, et al.From:The Lancet Infectious Diseases (Vol. 22, Issue 1) Peer-Reviewed

  Jan. 20221,672 words Article

   Abstract Only

• Medical countermeasures against henipaviruses: a review and public health perspective.

  Authors:Raúl Gómez Román, Nadia Tornieporth, Neil George Cherian, Amy C Shurtleff, Maïna L'Azou Jackson, Debra Yeskey, et al.From:The Lancet Infectious Diseases (Vol. 22, Issue 1) Peer-Reviewed

  Jan. 2022230 words Brief article

   Abstract Only

• Efficacy and safety of co-administered ivermectin and albendazole in school-aged children and adults infected with Trichuris trichiura in Cote d'Ivoire, Laos, and Pemba Island, Tanzania: a double-blind, parallel-group, phase 3, randomised controlled trial.

  Authors:Eveline Hürlimann, Ladina Keller, Chandni Patel, Sophie Welsche, Jan Hattendorf, Said M Ali, et al.From:The Lancet Infectious Diseases (Vol. 22, Issue 1) Peer-Reviewed

  Jan. 2022611 words Article

   Abstract Only